Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Innovative Approaches for Intestinal Dysbiosis: Integrating Nanotechnology into Pharmacological Interventions

Author(s): Virna Margarita Martín Giménez and Walter Manucha*

Volume 29, Issue 21, 2023

Published on: 03 August, 2023

Page: [1629 - 1631] Pages: 3

DOI: 10.2174/1381612829666230803111610

Price: $65

conference banner
Next »
[1]
Belizário JE, Faintuch J. Microbiome and gut dysbiosis. Experientia Suppl 2018; 109: 459-76.
[http://dx.doi.org/10.1007/978-3-319-74932-7_13] [PMID: 30535609]
[2]
Martín Giménez VM, Rukavina Mikusic NL, Lee HJ, García Menéndez S, Choi MR, Manucha W. Physiopathological mechanisms involved in the development of hypertension associated with gut dysbiosis and the effect of nutritional/pharmacological interventions. Biochem Pharmacol 2022; 204: 115213.
[http://dx.doi.org/10.1016/j.bcp.2022.115213] [PMID: 35985404]
[3]
Robles-Vera I, de la Visitación N, Sánchez M, et al. Mycophenolate improves brain–gut axis inducing remodeling of gut microbiota in DOCA-Salt hypertensive rats. Antioxidants 2020; 9(12): 1199.
[http://dx.doi.org/10.3390/antiox9121199] [PMID: 33260593]
[4]
Santhiravel S, Bekhit AEDA, Mendis E, et al. The impact of plant phytochemicals on the gut microbiota of humans for a balanced life. Int J Mol Sci 2022; 23(15): 8124.
[http://dx.doi.org/10.3390/ijms23158124] [PMID: 35897699]
[5]
Zhang Z, Zhao J, Tian C, et al. Targeting the gut microbiota to investigate the mechanism of lactulose in negating the effects of a high‐salt diet on hypertension. Mol Nutr Food Res 2019; 63(11): 1800941.
[http://dx.doi.org/10.1002/mnfr.201800941] [PMID: 30825362]
[6]
Li Y, Zafar S, Salih Ibrahim RM, et al. Exercise and food supplement of vitamin C ameliorate hypertension through improvement of gut microflora in the spontaneously hypertensive rats. Life Sci 2021; 269: 119097.
[http://dx.doi.org/10.1016/j.lfs.2021.119097] [PMID: 33482189]
[7]
Hsu CN, Hou CY, Chang-Chien GP, et al. Maternal resveratrol therapy protected adult rat offspring against hypertension programmed by combined exposures to asymmetric dimethylarginine and trimethylamine-N-oxide. J Nutr Biochem 2021; 93: 108630.
[http://dx.doi.org/10.1016/j.jnutbio.2021.108630] [PMID: 33798707]
[8]
Robles-Vera I, de la Visitación N, Toral M, et al. Changes in gut microbiota induced by doxycycline influence in vascular function and development of hypertension in DOCA-salt rats. Nutrients 2021; 13(9): 2971.
[http://dx.doi.org/10.3390/nu13092971] [PMID: 34578849]
[9]
Galla S, Chakraborty S, Cheng X, et al. Disparate effects of antibiotics on hypertension. Physiol Genomics 2018; 50(10): 837-45.
[http://dx.doi.org/10.1152/physiolgenomics.00073.2018] [PMID: 30095376]
[10]
Galla S, Chakraborty S, Cheng X, et al. Exposure to amoxicillin in early life is associated with changes in gut microbiota and reduction in blood pressure: Findings from a study on rat dams and offspring. J Am Heart Assoc 2020; 9(2): e014373.
[http://dx.doi.org/10.1161/JAHA.119.014373] [PMID: 31928175]
[11]
Yang T, Aquino V, Lobaton GO, et al. Sustained captopril‐induced reduction in blood pressure is associated with alterations in gut‐brain axis in the spontaneously hypertensive rat. J Am Heart Assoc 2019; 8(4): e010721.
[http://dx.doi.org/10.1161/JAHA.118.010721] [PMID: 30755073]
[12]
Robles-Vera I, Toral M, Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol 2020; 177(9): 2006-23.
[http://dx.doi.org/10.1111/bph.14965] [PMID: 31883108]
[13]
Qi YZ, Jiang YH, Jiang LY, Shao LL, Yang XS, Yang CH. An insight into intestinal microbiota of spontaneously hypertensive rats after valsartan administration. Dose Response 2021; 19(2)
[http://dx.doi.org/10.1177/15593258211011342] [PMID: 33994888]
[14]
Giménez VMM, Fuentes LB, Kassuha DE, Manucha W. Current drug nano-targeting strategies for improvement in the diagnosis and treatment of prevalent pathologies such as cardiovascular and renal diseases. Curr Drug Targets 2019; 20(14): 1496-504.
[http://dx.doi.org/10.2174/1389450120666190702162533] [PMID: 31267869]
[15]
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20(2): 101-24.
[http://dx.doi.org/10.1038/s41573-020-0090-8] [PMID: 33277608]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy